Danaher Corp (N:DHR)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 2200 Pennsylvania Ave NW Ste 800W
WASHINGTON DC 20037-1731
Tel: 1-202-8280850
Website: https://www.danaher.com
IR: See website
<
Key People
Steven M. Rales
Chairman of the Board
Daniel A. Raskas
Senior Vice President - Corporate Development
Rainer M. Blair
President, Chief Executive Officer, Director
Matthew R. McGrew
Chief Financial Officer, Executive Vice President
Christopher P. Riley
Executive Vice President
Joakim Weidemanis
Executive Vice President
Jose-Carlos Gutierrez-Ramos
Senior Vice President, Chief Science Officer
Brian W. Ellis
Senior Vice President, General Counsel
Georgeann F. Couchara
Senior Vice President - Human Resources
William H. King
Senior Vice President - Strategic Development
   
Business Overview
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Financial Overview
For the three months ended 29 March 2024, Danaher Corp revenues decreased 3% to $5.8B. Net income applicable to common stockholders excluding extraordinary items decreased 11% to $1.09B. Revenues reflect Biotechnology segment decrease of 18% to $1.52B. Net income also reflects Biotechnology segment income decrease of 45% to $325M, Life Sciences segment income decrease of 27% to $235M, Other segment loss increase of 1% to $78M.
Employees: 61,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $195,104M as of Mar 29, 2024
Annual revenue (TTM): $23,737M as of Mar 29, 2024
EBITDA (TTM): $7,441M as of Mar 29, 2024
Net annual income (TTM): $4,069M as of Mar 29, 2024
Free cash flow (TTM): $4,763M as of Mar 29, 2024
Net Debt Last Fiscal Year: $11,132M as of Mar 29, 2024
Shares outstanding: 740,686,541 as of Apr 18, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.